In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.
On je odobren u Japanu oktobra 2006. za hiponatremiju (niske nivoe krvnog natrijuma) uzrokovane sindromom neodgovarajućeg izlučivanja antidiuretskog hormona (SIADH) usled tumora koji proizvodi ADH.